Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
09960 康聖環球基因技術
Kindstar Globalgene Technology
Listing Date2021/07/16
Listing Price9.780
  • 5.350 0.000 (0.000%)    Sink Below Listing Price
  • 15-min delayed, last update: 20/10/2021 08:30
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    50 lot
  • One Lot Success Rate

Kindstar Globalgene Technology is an independent esoteric clinical testing service provider in China. It has the largest esoteric testing portfolio among all the independent esoteric testing providers in China, with over 3,500 testing items in its service menu, which includes over 2,300 testing items for hematology. Over 1,100 testing items were developed fully internally, and approximately 2,400 testing items were developed by or in-licensed from third parties.

According to Frost & Sullivan. The Group has established a leading position in China’s independent hematology esoteric clinical testing industry, accounting for the largest or 42.3% of the market share by revenue in 2020, as well as a leading position in the overall independent esoteric testing market, accounting for the fifth largest or 4.1% market share in terms of revenue.

The testing services include: clinical testing services, where it provides comprehensive testing services to hospitals, or through them, individual patients, and testing services for R&D projects and others, where it provides testing services for CROs, sponsors of clinical trials, pharmaceutical companies and research institutes. It is headquartered in Wuhan, Hubei Province, and are maintaining and operating 7 Proprietary Labs across China, including in Wuhan, Beijing, Shanghai, Chengdu, Urumqi and in Tianjin.

The Group provides clinical testing services to hospitals and their patients primarily in six major specialty areas in esoteric testing, including hematology, genetic diseases and rare diseases, infectious diseases, oncology, neurology and maternity-related diseases. Extensive customer base includes hospitals, CROs, pharmaceutical companies and others.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot500
No. of Offer Shares226m shares
No. of International Offer Shares204m shares
No. of HK Offer Shares22.64m shares
Offer Price$8.60 - $9.78
Registrar & Transfer OfficeTricor Investor Services
Stock Code9960
Sponsor(s)Goldman Sachs (Asia) L.L.C.; China International Capital Corporation Hong Kong Securities Limited; Credit Suisse (Hong Kong) Limited
Underwriter(s)Goldman Sachs (Asia) L.L.C.; China International Capital Corporation Hong Kong Securities Limited; Credit Suisse (Hong Kong) Limited; VMS Securities Limited; Guotai Junan Securities (Hong Kong) Limited; Futu Securities International (Hong Kong) Limited
Application PeriodJun 29 (Tue) - Noon, Jul 7 (Wed)
Price Determination DateOn or Before 5pm, Jul 8 (Thu)
Result Announcement DateOn or Before Jul 15 (Thu)
Dispatch of Shares and Refund ChequesOn or Before Jul 15 (Thu)
Dealings in Shares commence onJul 16, 2021. (Fri)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
ExecutiveHuang Shiang (Chairman) Tu Zanbing, Chai Haijie
Non-ExecutiveHuang Zuie-Chin, Peng Wei, Huang Lu
Independent Non-ExecutiveYao Shanglong, Xia Xinping, Gu Huaming
Director Huang Shiang and related parties16.05%
Huang Zuie-Chin10.37%
Morningside Holdings (Asia)10.06%
CPE Holdings International8.87%
(Year ended Dec 31)
Gross Profit460,981452,214378,396
Pre-Taxed Profit(962,352)(168,605)(59,415)
Attributable Profit for the period(974,020)(169,788)(52,674)
Offer Price$8.60 - $9.78
Capitalization$7,788m - $8,857m
Unaudited pro forma adj NAV / share$3.34 - $3.62
Assuming the offer price being at the mid-point of $9.19, the net proceeds raised would be HK$1,931.1m, of which:
* $675.9m (35.0%) to conduct marketing and promotional activities and the expansion of our sales and marketing team in China;
* $386.2m (20.0%) to research and development of existing esoteric testing service lines;
* $289.7m (15.0%) to develop and commercialization of new lines of esoteric testing services;
* $96.6m (5.0%) to fund expansion by acquiring attractive technology or testing-related companies;
* $193.1m (10.0%) to increase testing capacity;
* $96.6m (5.0%) to overseas expansion; and
* the balance of $193.1m (10.0%) as additional working capital.
Code Name Nominal Change %Change
01931IVD MEDICALunchange2.9300.0000.000%
06606NH HEALTH-Bunchange33.2500.0000.000%
08622HUAKANG BIOMEDunchange0.2450.0000.000%
09960KINDSTAR GLOBALunchange5.3500.0000.000%
15-min delayed, last updated: 20/10/2021 08:31
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.